Hypokalaemia in Healthy Volunteers after Single and Multiple Doses of Formoterol or Salbutamol

[1]  P. Zweers,et al.  Long-term efficacy of formoterol compared to salbutamol , 2007, Lung.

[2]  P. Molenaar,et al.  β-Adrenoceptor regulation and functional responses in the guinea-pig following chronic administration of the long-acting β2-adrenoceptor agonist formoterol , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  P. Giusti,et al.  Lack of anticonvulsant tolerance and benzodiazepine receptor down regulation with imidazenil in rats , 1996, British journal of pharmacology.

[4]  J. Smeets,et al.  Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients , 1995, Fundamental & clinical pharmacology.

[5]  D. Yates,et al.  Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. , 1995, American journal of respiratory and critical care medicine.

[6]  E. Bixler,et al.  Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. , 1995, Pharmacology.

[7]  H. Chrystyn,et al.  Standards for Bioequivalence of Inhaled Products , 1994, Clinical pharmacokinetics.

[8]  A. Chetta,et al.  Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. , 1993, Annals of allergy.

[9]  A. Tattersfield.  Clinical pharmacology of long-acting β-receptor agonists , 1993 .

[10]  P. Zweers,et al.  The onset of action of formoterol, a new beta 2 adrenoceptor agonist. , 1993, International journal of clinical pharmacology, therapy, and toxicology.

[11]  J. Malo,et al.  Sustained improvement in asthma with long-term use of formoterol fumarate. , 1992, Annals of allergy.

[12]  H. Lemoine,et al.  Highly potent beta-2 sympathomimetics convert to less potent partial agonists as relaxants of guinea pig tracheae maximally contracted by carbachol. Comparison of relaxation with receptor binding and adenylate cyclase stimulation. , 1992, The Journal of pharmacology and experimental therapeutics.

[13]  R. Jonkers,et al.  Quantification of metoprolol beta 2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling. , 1992, Pulmonary Pharmacology.

[14]  R. Pauwels,et al.  Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. , 1992, Thorax.

[15]  D. Faulds,et al.  Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. , 1991, Drugs.

[16]  P. Brombacher,et al.  The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. , 1991, Chest.

[17]  P. O'Byrne,et al.  Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. , 1991, The American review of respiratory disease.

[18]  R. Koopmans,et al.  Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. , 1991, The Journal of pharmacology and experimental therapeutics.

[19]  J. Malo,et al.  Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. , 1990, The American review of respiratory disease.

[20]  N. Thomson,et al.  Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist. , 1990, Respiratory medicine.

[21]  K. Chung,et al.  Effect of formoterol, a long-lasting beta 2-adrenoceptor agonist, against methacholine-induced bronchoconstriction. , 1990, British journal of clinical pharmacology.

[22]  B. Lipworth,et al.  Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. , 1989, The American review of respiratory disease.

[23]  C. Löfdahl,et al.  Formoterol fumarate, a new β2‐adrenoceptor agonist , 1989 .

[24]  R. Koopmans,et al.  A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. , 1989, The Journal of pharmacology and experimental therapeutics.

[25]  R. Jonkers,et al.  Beta‐2‐adrenoceptor—mediated hypokalemia and its abolishment by oxprenolol , 1987, Clinical pharmacology and therapeutics.

[26]  M. Koulu,et al.  Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. , 1987, British journal of clinical pharmacology.

[27]  J. Haalboom,et al.  HYPOKALAEMIA INDUCED BY INHALATION OF FENOTEROL , 1985, The Lancet.

[28]  M. Brown,et al.  Hypokalemia from beta 2-receptor stimulation by circulating epinephrine. , 1983, The American journal of cardiology.

[29]  N. Burki,et al.  The effect of subcutaneously administered terbutaline on serum potassium in asymptomatic adult asthmatics. , 1984, The American review of respiratory disease.

[30]  Davies Ds.  The fate of inhaled terbutaline. , 1984 .

[31]  J. Reid,et al.  Effect of intravenous adrenaline on electrocardiogram, blood pressure, and serum potassium. , 1983, British heart journal.

[32]  T. Clausen,et al.  β2‐ADRENOCEPTORS MEDIATE THE STIMULATING EFFECT OF ADRENALINE ON ACTIVE ELECTROGENIC NA‐K‐TRANSPORT IN RAT SOLEUS MUSCLE , 1980 .

[33]  J. Palmer,et al.  Metabolic effects of salbutamol: comparison of aerosol and intravenous administration. , 1977, British medical journal.